{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-001181","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2021-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.511833+00:00","generated_at":"2026-06-29T16:40:49.681652+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Clearside reports Q2 2021 net loss $6.1M; OASIS Cohort 2 underway; XIPERE PDUFA Oct 30","bullets":["Net loss of $6.1M ($0.11/share) vs $5.8M ($0.13/share) in Q2 2020.","Revenue of $0.8M from partner licensing; cash $26.4M to fund ops into Q2 2022.","OASIS Phase 1/2a wet AMD: Cohort 1 met safety endpoints; Cohort 2 enrollment (0.1 mg dose) underway.","XIPERE NDA resubmission accepted; FDA PDUFA action date of October 30, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-001181","json":"https://secwatch.observer/filing/0000950170-21-001181.json","markdown":"https://secwatch.observer/filing/0000950170-21-001181.md","text":"https://secwatch.observer/filing/0000950170-21-001181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017021001181/0000950170-21-001181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017021001181/clsd-20210810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T16:40:49.681652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}